A Potential New Tool for Addiction Disorder Treatment

GLP-1 receptor agonists (often called “GLP-1s”) are medicines commonly used to treat type 2 diabetes and help with weight loss.

Researchers are now looking at whether these medicines might also help with addiction. Early studies and patient reports suggest that some people taking medicines like semaglutide or tirzepatide notice fewer cravings—for example, they may feel less urge to drink alcohol or smoke.

Because of these reports, more studies are underway to see if GLP-1s could help treat different substance use disorders, including alcohol, nicotine, and opioids.

One possible explanation comes from the phenomenon patients describe as “food noise.” If GLP-1s dampen the intrusive reward-driven thoughts associated with eating, researchers are asking whether they might also quiet the compulsive cravings that characterize addiction.

GLP-1 receptor agonists (GLP-1s) are medicines that mimic a natural hormone your body releases after you eat. Researchers are studying several ways they *might* help with cravings and addiction-related behaviors:

- **They may “turn down” the brain’s reward signal. ** GLP-1 receptors are found in brain areas involved in motivation and reward (the same circuits that can be activated by alcohol, nicotine, and other substances). In animal studies, activating these receptors can reduce drug- and alcohol-seeking behavior, suggesting the “reward hit” may feel less intense.

- **They may reduce cue-triggered cravings. ** Cravings are often sparked by triggers (stress, places, routines). Early research suggests GLP-1 signaling may make those triggers less powerful, so urges are easier to ignore.

- **They may improve appetite/satiety signaling that overlaps with craving pathways. ** The brain systems that regulate hunger and “wanting” overlap with systems involved in cravings. Because GLP-1s increase feelings of fullness and reduce food “noise” for many people, researchers think a similar effect could happen with substance cravings.

- **They may affect stress and impulse control.** Some studies suggest GLP-1 pathways interact with stress hormones and brain regions involved in self-control and decision-making, which could potentially make it easier to pause before acting on an urge.

- **Indirect effects may also matter. ** Better blood sugar stability, improved sleep, and weight-related health improvements could reduce stress on the body—factors that sometimes worsen cravings—though this wouldn’t be the main mechanism.

Important caveat: **Most of the strongest evidence so far is from animal studies and observational human data. ** Observational studies can show links, but they can’t prove GLP-1s *cause* lower substance use. Clinical trials are underway to answer that.

What the Evidence Shows

Dr. Michael Weaver, an addiction specialist at UTHealth Houston, says early research on GLP‑1 medications (the drugs used for diabetes and weight loss) shows interesting early signs that they might help with addiction. But he stresses that scientists still have a lot to learn, and solid answers are still years away.

One big question is how these medications actually work in the brain. Researchers don’t yet know whether GLP‑1s directly reduce addiction or whether they simply lower all types of reward‑seeking behavior in general.

Some evidence suggests the second idea may be true. In animal studies, GLP‑1s reduce not only drug‑seeking but also overeating and interest in other pleasurable activities. Brain scans in humans show less activity in the brain’s “reward centers” when people see cues related to food or drugs.

Doctors have also heard reports from patients saying they feel fewer cravings for food, alcohol, drugs, and even gambling. This supports the idea that GLP‑1s may act on a shared reward pathway in the brain. Still, researchers caution that we don’t yet have enough targeted studies to say for sure.

What We Still Don’t Know

Another major question is how selective these effects are. Reward‑seeking covers a huge range of behaviors. It’s unclear whether GLP‑1s reduce cravings for harmful substances while still allowing people to enjoy normal pleasures, stay motivated, and pursue goals.

This matters clinically. Doctors want to know whether GLP‑1s can reduce unhealthy cravings without causing emotional numbness or loss of enjoyment. Some people have reported feeling “flat” or less pleasure, but large studies have not shown increased depression or suicide risk. In fact, some research suggests possible mental‑health benefits.

Even with growing optimism, many questions remain, including:

• Which patients benefit the most

• What dose works best

• How long treatment should last

• Whether benefits continue after stopping the medication

• How GLP‑1s interact with mental‑health conditions

• Whether they should be used alone or with existing addiction medications

• Whether they help people who do not have obesity.

  
  

Right now, the research simply isn’t far enough along to answer these questions.

Where GLP‑1s Might Fit in the Future

We won’t know exactly how GLP‑1s fit into addiction treatment until more research is done. Several clinical trials will report results in the next 1–2 years, but larger and longer studies will be needed to understand long‑term safety, relapse prevention, and durability of benefits.

Some doctors are already prescribing GLP‑1s “off‑label” for alcohol use disorder, especially for patients who also have obesity or diabetes.

If GLP‑1s eventually become part of standard addiction care, access and fairness will be important. Right now, people of color and those with lower incomes are less likely to receive GLP‑1 medications, and Medicaid does not cover them for obesity. Clear prescribing guidelines would be needed to ensure fair use.

Even with the excitement around GLP‑1s, experts emphasize that they are not ready to replace proven addiction treatments. Many people with addiction still do not receive the medications we already know work.

REFERENCES: GLP-1s for Addiction: Are We There Yet? - Medscape - July 02, 2026.

(Paraphrased from an article by Medscape Medical News, quoting Dr. Michael Weaver.)

written by Cyndi Obermaier, RN

Assessed and Endorsed by the MedReport Medical Review Board